coelenterazine and tivozanib

We developed a novel approach to assess tumor vascularity using recombinant Gaussia luciferase (rGluc) protein and bioluminescence imaging. Upon intravenous injection of rGluc followed by its substrate coelenterazine, non-invasive visualization of tumor vascularity by bioluminescence imaging was possible. We applied this method for longitudinal monitoring of tumor vascularity in response to the anti-angiogenic drug tivozanib. This simple and sensitive method could be extended to image blood vessels/vasculature in many different fields.

Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Copepoda; Humans; Imidazoles; Luciferases; Luminescent Agents; Luminescent Measurements; Neoplasm Transplantation; Neoplasms; Phenylurea Compounds; Pyrazines; Quinolines; Recombinant Proteins; Treatment Outcome